Jeannette Lo - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jeannette Lo

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Kidney International|June 7, 2025

Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathyLaura Kooienga, Jeannette Lo, Eun Young Lee, et al.

Frontiers in Immunology|April 20, 2019

Evaluation of <i>in vitro</i> Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and AggregatesHannah Morgan, Su-Yi Tseng, Yann Gallais, et al.

Kidney International Reports|May 28, 2026

Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root CausesJohn Dulos, Joost Kreijtz, Paul Vink, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Kidney International|June 7, 2025

Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathyLaura Kooienga, Jeannette Lo, Eun Young Lee, et al.

Frontiers in Immunology|April 20, 2019

Evaluation of <i>in vitro</i> Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and AggregatesHannah Morgan, Su-Yi Tseng, Yann Gallais, et al.

Kidney International Reports|May 28, 2026

Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root CausesJohn Dulos, Joost Kreijtz, Paul Vink, et al.

Pageof 2